<div class="entities" style="line-height: 2.5; direction: ltr">Name:  [**Known lastname 17298**], [**Known firstname **]                     Unit No:  [**Numeric Identifier 17299**]<br><br>Admission Date:  [**2148-3-25**]     Discharge Date:  [**2148-4-9**]<br><br>Date of Birth:   [**2097-9-27**]     Sex:  M<br><br>Service:  Transplant surgery.  #58<br><br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ADDENDUM
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
:<br><br>The patient was anticipating discharge to the [**Hospital 17300**]<br>Rehabilitation Center on [**2148-4-4**].  However, the patient<br>was found to have rising liver function tests with a peak<br>total bilirubin level of 4.5 and, therefore, underwent an<br>endoscopic retrograde cholangiopancreatography procedure on<br>this date.  This study demonstrated diffuse 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    dilatation
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
 at the<br>proximal site of the biliary anastomosis, compatible with an<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    anastomotic
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    stricture
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  A 5 cm by #10 French plastic biliary<br>stent was, therefore, placed.<br><br>Following this procedure, the patient felt well clinically<br>without abdominal pain.  However, his 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    amylase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    lipase
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 were<br>slightly elevated the day following the procedure and he was,<br>therefore, monitored for possible post endoscopic retrograde<br>cholangiopancreatography 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    pancreatitis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Reason</span>
</mark>
.  The patient was<br>maintained on his 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intravenous
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    diuretics
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and his liver<br>function tests slowly returned to [**Location 1867**] following the<br>procedure.  However, on hospital day number 13, the patient<br>complained of 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    left
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    upper
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    extremity
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    swelling
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
, which he states<br>had been there for some months prior to admission.  However,<br>given the presence of a left subclavian central venous line,<br>and this new finding on examination, a duplex ultrasound was<br>ordered for the left upper extremity which was consistent<br>with a 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    deep
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    venous
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  The patient was, therefore,<br>started on a 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    heparin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    drip
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 to be titrated to a goal PTT<br>between 40 to 60 seconds. He was also started on 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Coumadin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 5<br>mg 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    daily
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Frequency</span>
</mark>
 towards a 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    goal
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    INR
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    of
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    .
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    0
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    to
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    2
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    .
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>

<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    5
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  At this time, the<br>patient was progressing well with physical therapy and was<br>discharged to the [**Hospital 17300**] Rehabilitation Center on hospital<br>day number 16, on a 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    heparin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    drip
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
, along with 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intravenous
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
<br>
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 and 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Coumadin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
.  His central venous line was removed<br>prior to discharge.  His 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    heparin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    drip
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 may be discontinued<br>once his INR reaches a level of 2.0.  He should be treated<br>for 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Coumadin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    for
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    three
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Duration</span>
</mark>
 
<mark class="entity" style="background: rgb(46, 204, 113); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    months
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Duration</span>
</mark>
 given his left upper extremity<br>
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    deep
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    vein
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Reason</span>
</mark>
 
<mark class="entity" style="background: rgb(211, 84, 0); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    thrombosis
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Reason</span>
</mark>
.  He will maintain his 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Lasix
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 dose at 
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    80
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Strength</span>
</mark>
<br>
<mark class="entity" style="background: rgb(230, 126, 34); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    mg
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Strength</span>
</mark>
 
<mark class="entity" style="background: rgb(149, 165, 166); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    intravenous
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Route</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    twice
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    a
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    day
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
 until his follow-up appointment on<br>[**2148-4-18**].  He is to have his laboratory studies drawn<br>
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    twice
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">B-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    weekly
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>

<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    ,
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    on
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Monday
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    and
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">I-Frequency</span>
</mark>
 
<mark class="entity" style="background: rgb(241, 196, 15); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Thursday
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">L-Frequency</span>
</mark>
, and faxed to the<br>transplant center for adjustment of his 
<mark class="entity" style="background: rgb(52, 152, 219); padding: 0.45em 0.6em; margin: 0 0.25em; box-shadow: 2px 4px 6px rgba(0, 0, 0, 0.699); border-radius: 0.35em;">
    Cyclosporin
    <span style="font-size: 0.8em; font-weight: bold; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">U-Drug</span>
</mark>
 dosing.<br>This level is to be drawn two hours after his morning dose.<br>The patient was instructed to call the transplant center if<br>he had any other questions or concerns.<br><br><br><br><br><br><br><br><br><br>                          [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern4) 51**], M.D.,PH.D.[**MD Number(3) 9110**]<br><br>Dictated By:[**Last Name (NamePattern1) 7438**]<br><br>MEDQUIST36<br><br>D:  [**2148-4-9**]  06:13<br>T:  [**2148-4-9**]  06:16<br>JOB#:  [**Job Number 17301**]<br></div>